ClinicalTrials.gg
TerminatedNCT03486327Updated Aug 23, 2024Results posted

Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions

A Phase 2 interventional study of BR55 in Pancreatic Ductal Adenocarcinoma, sponsored by Bracco Diagnostics, Inc. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-23.

Sponsored by Bracco Diagnostics, Inc (part of Bracco) · Phase 2, Interventional, and Diagnostic

Why this study was terminated
Sponsor decision; expiration of available study agent due to long recruitment timeline.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an exploratory, single center, open label, parallel-dose, and prospective study of BR55 contrast-enhanced ultrasonography (CEUS) for characterization of solid pancreatic lesions in subjects with suspected pancreatic ductal adenocarcinoma (PDAC) using transabdominal US.

Read the detailed description

Approximately twenty-four (24) subjects with suspected PDAC and scheduled to undergo surgical resection within 30 days (but not before 24 hours) after the transabdominal BR55 CEUS examination will be enrolled into 3 dose groups, 0.03, 0.05, and 0.08 mL/kg, with a maximum of 8 patients in each dose group.

02

Conditions studied

  • Pancreatic Ductal Adenocarcinoma
03

In context

Lead sponsor

Bracco Diagnostics, Inc is the lead sponsor of 49 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Enroll a subject in this study if the subject meets the following inclusion criteria:

  • Is at least 18 years of age;
  • Has at least one solid pancreatic lesion;
  • Is scheduled to undergo surgical resection for suspected PDAC not earlier than 24 hours and not later than 30 days following BR55 administration;
  • Provides written and is willing to comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

Exclude a subject from this study if the subject does not fulfill the inclusion criteria, or if any of the following conditions are observed:

  • Is a pregnant or lactating female. Exclude the possibility of pregnancy:

    • by testing on site at the institution (serum βHCG) within 24 hours prior to the start of product (IP) administration,
    • by surgical history (e.g., tubal ligation or hysterectomy),
    • by status with a minimum 1 year without menses;
  • Has undergone prior systemic therapy for pancreatic cancer;
  • Has history of any concurrent ;
  • Has history of any clinically unstable cardiac condition including class III/IV congestive heart failure;
  • Has had any severe cardiac rhythm disorders within 7 days prior to enrolment;
  • Has severe pulmonary hypertension (pulmonary artery pressure > 90mmHg) or uncontrolled systemic hypertension and/or respiratory distress syndrome;
  • Has open and/or non-healing wounds in the chest, abdomen and pelvis;
  • Has other systemic vascular abnormalities associated with neovascularization, such as macular degeneration, that in the opinion of the investigator could significantly affect the ability to evaluate the effects of BR55;
  • Is participating in a clinical trial or has participated in another trial with an investigational compound within the past 30 days prior to enrolment;
  • Has previously been enrolled in and completed this study;
  • Has any known allergy to one or more of the ingredients of the IP or to any other contrast media;
  • Is determined by the Investigator that the subject is clinically unsuitable for the study;
  • Has had major surgery, including laparoscopic surgery within 3 months prior to enrolment;
  • Has history of pancreatic surgery (e.g., cyst removal);
  • Has acute pancreatic abnormalities (acute pancreatitis or trauma).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    0.03mL/kg Dose Group

    A group of up to 8 subjects to receive a single dose of BR55 at 0.03mL/kg.

    Drug: BR55

  • Experimental
    0.05mL/kg Dose Group

    A group of up to 8 subjects to receive a single dose of BR55 at 0.05mL/kg.

    Drug: BR55

  • Experimental
    0.08mL/kg Dose Group

    A group of 8 subjects to receive a single dose of BR55 at 0.08mL/kg.

    Drug: BR55

Interventions

  • DrugBR55

    A novel targeted ultrasound contrast agent

06

What researchers measure

Primary outcomes

  1. 1. Visual Assessment of Enhancement

    BR55-enhanced images will be visually assessed using a 3-point scale (no enhancement, weak enhancement, strong enhancement).

    Time frame: Up to 24 hours post-dose on Day 1

  2. 2. Adverse Events

    Number of participants who received the contrast agent and experienced an adverse event.

    Time frame: From the time of signing Informed Consent through 24 hours post-dose, up to a maximum of 11 days

07

Results

Posted Aug 23, 2024

Participant flow

Participant flow — Overall Study
Milestone0.03mL/kg Dose Group0.05mL/kg Dose Group0.08mL/kg Dose Group
Started400
Completed400
Not completed000

Outcome measures

Primary1. Visual Assessment of Enhancement

BR55-enhanced images will be visually assessed using a 3-point scale (no enhancement, weak enhancement, strong enhancement).

Time frame:
Up to 24 hours post-dose on Day 1
Reported as:
Count of participants · Participants
1. Visual Assessment of Enhancement
Participants0.03mL/kg Dose Group0.05mL/kg Dose Group0.08mL/kg Dose Group
No enhancement0——
Weak enhancement3——
Strong enhancement1——
Primary2. Adverse Events

Number of participants who received the contrast agent and experienced an adverse event.

Time frame:
From the time of signing Informed Consent through 24 hours post-dose, up to a maximum of 11 days
Reported as:
Count of participants · Participants
2. Adverse Events
Participants0.03mL/kg Dose Group0.05mL/kg Dose Group0.08mL/kg Dose Group
2. Adverse Events200

Adverse events

Collected over Safety monitoring began at the time of signing Informed Consent and continued for 24 hours after BR55 administration, up to a maximum of 11 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.03mL/kg Dose Group0/4 (0%)0/4 (0%)2/4 (50%)
0.05mL/kg Dose Group———
0.08mL/kg Dose Group———
Most frequent other events
Most frequent other events
Event0.03mL/kg Dose Group0.05mL/kg Dose Group0.08mL/kg Dose Group
PruritusSkin and subcutaneous tissue disorders1/4——
VomitingGastrointestinal disorders1/4——

Baseline characteristics

As of July 31, 2021, enrollment was terminated for Study BR55-110 due to expiration of available BR55. Therefore, only 4 participants were enrolled in the first cohort of this study (0.03 mL/kg). No participant was enrolled in the 0.05 mL/kg or 0.08 mL/kg groups.

Age, Categorical
Age, Categorical(Participants)0.03mL/kg Dose Group0.05mL/kg Dose Group0.08mL/kg Dose GroupTotal
<=18 years0——0
Between 18 and 65 years3——3
>=65 years1——1
Age, Continuous
Age, Continuous(years)0.03mL/kg Dose Group0.05mL/kg Dose Group0.08mL/kg Dose GroupTotal
Mean65.5 (60 to 78)——65.5 (60 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)0.03mL/kg Dose Group0.05mL/kg Dose Group0.08mL/kg Dose GroupTotal
Female0——0
Male4——4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)0.03mL/kg Dose Group0.05mL/kg Dose Group0.08mL/kg Dose GroupTotal
American Indian or Alaska Native1——1
Asian1——1
Native Hawaiian or Other Pacific Islander0——0
Black or African American0——0
White2——2
More than one race0——0
Unknown or Not Reported0——0
Region of Enrollment
Region of Enrollment(participants)0.03mL/kg Dose Group0.05mL/kg Dose Group0.08mL/kg Dose GroupTotal
United States4——4
Total Volume (mL) Injected
Total Volume (mL) Injected(mL)0.03mL/kg Dose Group0.05mL/kg Dose Group0.08mL/kg Dose GroupTotal
Mean2.00 (1.60 to 2.37)——2.00 (1.60 to 2.37)
08

Study locations

1 site
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Nov 2020, 27 months.

Results were first posted in Aug 2024, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2018
First posted
Apr 3, 2018
StartActual
Jul 19, 2018
Primary completionActual
Nov 13, 2020
CompletionActual
Jul 31, 2021
Results first posted
Aug 23, 2024
Last update
Aug 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03486327
Responsible party
Sponsor
First posted
Apr 3, 2018
Start date
Jul 19, 2018
Primary completion
Nov 13, 2020
Completion
Jul 31, 2021
Results posted
Aug 23, 2024
Last update
Aug 23, 2024

Study contacts

Maria Luigia Storto, MD
study director · Bracco Diagnostics, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BR55

Start the discussion